High-dose chemotherapy and autologous stem cell transplantation in elderly primary CNS lymphoma patients - retrospective chart review
Completed
- Conditions
- C85.9Non-Hodgkin lymphoma, unspecified
- Registration Number
- DRKS00009037
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Immunocompetent patients with biopsy proven PCNSL who underwent HDT-ASCT, age at diagnosis >/=65 years
Exclusion Criteria
Congenital or acquired immunodeficiency, age < 65 years
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS)<br>
- Secondary Outcome Measures
Name Time Method Remission status before HCT-ASCT<br>Adverse events during HCT-ASCT<br>Remission status after HCT-ASCT<br>Overall Survival (OS)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie HDT-ASCT efficacy in elderly PCNS lymphoma patients?
How does HDT-ASCT compare to standard-of-care therapies for C85.9 in older adults?
Which biomarkers correlate with successful HDT-ASCT outcomes in primary CNS lymphoma?
What are the most common adverse events associated with HDT-ASCT in geriatric PCNS patients?
Are there combination therapies showing better outcomes than HDT-ASCT for elderly PCNS lymphoma?